Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011–2019 oncology clinic electronic health record data

Figures & data

Table 1. Baseline demographic/clinical characteristics at multiple myeloma diagnosis.

Patient characteristic	2011–2019 (n = 10,553)
	n	%
Practice type, community^a	9245	87.6
Gender, male	5686	53.9
Age, years
18–49	593	5.6
50–64	3139	29.7
65–74	3425	32.5
75+	3396	32.2
Race/ethnicity
White	6382	60.5
Black or African American	1682	15.9
Other	1159	11.0
Asian	189	1.8
Hispanic or Latino	40	0.4
Missing	1101	10.4
International Staging System Stage at diagnosis
Stage I	1829	17.3
Stage II	1786	16.9
Stage III	1753	16.6
Missing	5185	49.1
Cytogenetic risk at diagnosis
Standard	1089	10.3
High risk: del(17p), t(4;14), t(14;16)	7429	70.4
Missing	2035	19.3
Hypercalcemia at diagnosis	358	3.4
Anemia at diagnosis	4509	42.7
Renal insufficiency at diagnosis	853	8.1
Eastern Cooperative Oncology Group score at diagnosis
0	1500	14.2
1	1448	13.7
2	568	5.4
3	193	1.8
4	11	0.1
Missing	6833	64.7

^aThe remaining patients were treated in academic settings.

Table 2. Number of patients in subgroups.

Outcome	N
Frontline-treated patients by multiple myeloma diagnosis year
2011–2012	1264
2013–2014	2092
All patients by lines of therapy
1	4446
2	2309
3	1227
4	738
5+	850

Figure 1. Multiple myeloma treatments over time. (A) Top regimens of multiple myeloma patients at line of therapy by treatment initiation year. The proportion of patients receiving different regimens is shown over time in 2-year increments from 2012 to 2019. Dex: dexamethasone; IMiD: immunomodulatory imide drug; MoAB: monoclonal antibody; PI: proteasome inhibitor. (B) Trends in line of therapy and regimen combinations by treatment initiation year. The proportion of patients receiving monotherapy, doublet, triplet, quad, or other regimens is shown over time in 2-year increments from 2012 to 2019.

Figure 2. Multiple myeloma survival. (A) Trends in overall survival of multiple myeloma patients by line of therapy. Shown is survival by LOT 1 to LOT 5 for years 2011–2019. CI: confidence interval; LOT: line of therapy. (B) Trends in overall survival in frontline-treated multiple myeloma patients by year of diagnosis. Shown is survival for patients receiving first-line therapies by year of diagnosis, 2011–2012 or 2013–2014, i.e. for those years that had 5 years of follow-up data available, with the dotted line at the 5-year mark. CI: confidence interval.

Figure 3. Trends in treatment duration of multiple myeloma patients by line of therapy. Shown is treatment duration by LOT for years 2011 to 2019. CI: confidence interval; LOT: line of therapy; NE: not estimable.